ZA8 Stock Overview A clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Zymeworks Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Zymeworks Historical stock prices Current Share Price US$12.50 52 Week High US$14.80 52 Week Low US$7.40 Beta 1.12 1 Month Change 0% 3 Month Change 11.61% 1 Year Change 50.93% 3 Year Change -10.97% 5 Year Change -68.27% Change since IPO 16.50%
Recent News & Updates
Zymeworks Inc. Announces First Patient Dosed in First-In-Human Phase 1 Trial Nov 06
New major risk - Revenue and earnings growth Nov 03
Third quarter 2024 earnings released: US$0.39 loss per share (vs US$0.41 loss in 3Q 2023) Nov 01 Zymeworks Inc., Annual General Meeting, Dec 10, 2024 Oct 30
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers Oct 21
Zymeworks Inc. Announces Board and Committee Changes Oct 19 See more updates
Zymeworks Inc. Announces First Patient Dosed in First-In-Human Phase 1 Trial Nov 06
New major risk - Revenue and earnings growth Nov 03
Third quarter 2024 earnings released: US$0.39 loss per share (vs US$0.41 loss in 3Q 2023) Nov 01 Zymeworks Inc., Annual General Meeting, Dec 10, 2024 Oct 30
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers Oct 21
Zymeworks Inc. Announces Board and Committee Changes Oct 19 Zymeworks Inc. to Report Q3, 2024 Results on Oct 31, 2024 Oct 10
Zymeworks Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Zymeworks Inc. Announces the Appointment of Leone Patterson as Executive Vice President and Chief Business Officer, Effective September 1, 2024
Zymeworks Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 12
Zymeworks Inc. Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer Jun 13
New minor risk - Share price stability Jun 13
First quarter 2024 earnings released: US$0.41 loss per share (vs US$0.36 loss in 1Q 2023) May 03
Zymeworks Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 12 Zymeworks Inc. Removes Dr. Christopher Astle from the Positions of Senior Vice President
Zymeworks Inc. Announces Appointment of Neil Gallagher to Its Board of Directors and as Member of the Research and Development Committee, Effective April 2, 2024 Mar 28
Full year 2023 earnings released: US$1.72 loss per share (vs US$1.91 profit in FY 2022) Mar 07
Zymeworks Inc. to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting Mar 06
High number of new directors Mar 01
Zymeworks Inc. to Report Q4, 2023 Results on Mar 06, 2024 Feb 15
Zymeworks Announces Appointment of Dr. Alessandra Cesano to Its Board of Directors Feb 08
Investor sentiment improves as stock rises 18% Dec 28
Zymeworks Inc. Announces Changes to its Board Dec 09
Third quarter 2023 earnings released: US$0.41 loss per share (vs US$0.72 loss in 3Q 2022) Nov 09
Zymeworks Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 18 Zymeworks Inc., Annual General Meeting, Dec 07, 2023
New major risk - Revenue and earnings growth Aug 14
Second quarter 2023 earnings released: US$0.76 loss per share (vs US$0.97 loss in 2Q 2022) Aug 11
Zymeworks Inc. Appoints Carlos E. Campoy to the Board of Directors, Effective from June 30, 2023 Jun 30
Jazz Pharmaceuticals plc and Zymeworks Inc. Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers Jun 03
Zymeworks Inc. Announces Executive Changes May 19
Investor sentiment improves as stock rises 17% May 15
First quarter 2023 earnings released: US$0.36 loss per share (vs US$1.18 loss in 1Q 2022) May 10
Insufficient new directors Apr 02
Investor sentiment improves as stock rises 16% Apr 01
Investor sentiment deteriorates as stock falls 22% Mar 14
Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Phase 2 Trial Evaluating Zanidatamab in Her2-Expressing Metastatic Gastroesophageal Adenocarcinoma Jan 20
Zymeworks Inc. Removes Neil Josephson from the Position of Chief Medical Officer Jan 05
Insider recently sold €7.5m worth of stock Dec 30
Zymeworks Inc. Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab Dec 20
Zymeworks Inc. Announces New Clinical Data for Zanidatamab in Her2+ /Hr+ Metastatic Breast Cancer Presented At 2022 Sabcs Dec 10
Zymeworks Inc., Annual General Meeting, Dec 16, 2022 Nov 26
Third quarter 2022 earnings released: US$0.72 loss per share (vs US$1.17 loss in 3Q 2021) Nov 10
Zymeworks Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 19
Zymeworks Inc. Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) At European Society for Medical Oncology Annual Congress Sep 13
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers Sep 05
Zymeworks Inc. Appoints Mr. Neil Klompas as President Aug 06
Zymeworks Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 22
Zymeworks Inc. Appoints Dr. Paul Moore as Chief Scientific Officer, Effective July 18, 2022 Jun 28
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2-Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022 May 27
All Blue Falcons FZE cancelled the acquisition of the remaining 94.56% stake in Zymeworks Inc. (NYSE:ZYME). May 21
First quarter 2022 earnings released: US$1.18 loss per share (vs US$0.87 loss in 1Q 2021) May 06
Alan Barge Would Serve on Zymeworks Inc.'s Board May 05
Insider recently bought €19m worth of stock Apr 27
Zymeworks Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 20
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 02 Zymeworks Inc. Announces Promotion of Chris Astle to Senior Vice President
Chief Medical Officer recently bought €63k worth of stock Jan 13
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with Beigene and Associated Milestone Payment Dec 10
Zymeworks Inc. Announces New Clinical Data for the HER2-Targeted Bispecific Antibody, Zanidatamab, in Heavily Pretreated HER2-Positive Breast Cancer Dec 09
Third quarter 2021 earnings released: US$1.17 loss per share (vs US$1.43 loss in 3Q 2020) Nov 06
Zymeworks Inc. Announces New Clinical Data for Zanidatamab, A Her2-Targeted Bispecific Antibody, Demonstrate Promising Response Rates and Durability in First-Line Her2- Positive Gea Sep 19
Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress Sep 13
Zymeworks Inc. Announces Milestone Payment as Janssen Achieves First Patient Dosed for Its Bispecific Antibody Utilizing Zymeworks' Azymetric and EFECT Therapeutic Platforms Aug 05
Zymeworks Inc., Annual General Meeting, May 05, 2021 Feb 12
Zymeworks Inc. Announces Executive Changes Feb 10
Zymeworks Advances Her2 Bispecific Antibody-Drug Conjugate, Zw49, into Expansion Cohort Stage of Clinical Development Jan 29
Zanidatamab Data Highlight Durable Antitumor Activity in HER2-Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium Jan 16
Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application Dec 03
Zymeworks Inc. Announces Expansion of Zanidatamab Pivotal Trial in HER2-Amplified Biliary Tract Cancer in Asia in Collaboration with BeiGene, Ltd Dec 02
Zymeworks Inc. Receives Orphan Drug Designation from the European Commission for Her2-Targeted Bispecific Antibody Zanidatamab in Patients with Gastric Cancer Nov 20
Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2-Expressing Breast Cancer Nov 18
ImmunoPrecise Antibodies Ltd. Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks Sep 18 Shareholder Returns ZA8 DE Biotechs DE Market 7D 0.8% -3.5% -2.0% 1Y 50.9% -14.7% 6.9%
See full shareholder returns
Return vs Market: ZA8 exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is ZA8's price volatile compared to industry and market? ZA8 volatility ZA8 Average Weekly Movement 11.6% Biotechs Industry Average Movement 6.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: ZA8's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: ZA8's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas.
Show more Zymeworks Inc. Fundamentals Summary How do Zymeworks's earnings and revenue compare to its market cap? ZA8 fundamental statistics Market cap €933.41m Earnings (TTM ) -€108.94m Revenue (TTM ) €59.61m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ZA8 income statement (TTM ) Revenue US$62.20m Cost of Revenue US$124.66m Gross Profit -US$62.46m Other Expenses US$51.21m Earnings -US$113.67m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.65 Gross Margin -100.42% Net Profit Margin -182.75% Debt/Equity Ratio 0%
How did ZA8 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 17:13 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Zymeworks Inc. is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Martin Bloom Burton & Co. Arlinda Lee Canaccord Genuity Yigal Nochomovitz Citigroup Inc
Show 14 more analysts 
